Αποτελέσματα Αναζήτησης
5 Μαρ 2024 · A leading global vaccine developer has announced that their investigational vaccine candidate for Herpes Simplex Virus (HSV) is undergoing a phase 1/2 clinical trial for the first time in Europe, England, and the United States.
- Herpes Vaccine Candidate Advances in 2023 - Precision Vaccinations News
BioNTech's placebo-controlled, observer-blinded,...
- HSV Treatment Readies for Approval - Precision Vaccinations News
This update is essential, as there are no FDA-approved...
- Herpes Vaccine Candidate Advances in 2023 - Precision Vaccinations News
8 Ιαν 2023 · BioNTech's placebo-controlled, observer-blinded, two-dose-escalation study was launched on December 8, 2022, and is expected to enroll around 108 healthy adult volunteers. This first-in-human HSV vaccine study was last updated on January 5, 2023.
29 Μαρ 2023 · This update is essential, as there are no FDA-approved herpes vaccines available. However, there are two mRNA-based vaccine candidates. HSV treatments and preventive vaccines are in great demand.
10 Φεβ 2023 · NEW YORK and MAINZ, GERMANY, FEBRUARY 10, 2023 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the start of a Phase 1/2 trial exploring the safety, tolerability, and immunogenicity of the companies’ mRNA vaccine candidates against shingles (also known as herpes zoster, or HZ), a debilitating disease caused by the ...
21 Δεκ 2022 · First-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163. BNT163 is the first candidate from BioNTech’s infectious disease mRNA vaccine collaboration with the University of Pennsylvania to enter the clinic.
10 Νοε 2023 · This article explains the steps that have been taken thus far to develop vaccines for oral and genital herpes, the reasons why these vaccines are important, and the roadblocks keeping researchers from better preventing or controlling herpes infections.
The latest failures of most of the clinical herpes vaccines indicate that immunotherapeutic vaccine against HSV should be efficient in eliciting antigen-specific immune responses that contain reactivation of the virus, to control both recurrent lesions and viral shedding.
